- Home
- VTMX vs DYN Comparison
VTMX vs DYN Comparison
Compare VTMX & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTMX
- DYN
- Stock Information
- Founded
- VTMX 1998
- DYN 1984
- Country
- VTMX Mexico
- DYN United States
- Employees
- VTMX N/A
- DYN N/A
- Industry
- VTMX
- DYN Medicinal Chemicals and Botanical Products
- Sector
- VTMX
- DYN Health Care
- Exchange
- VTMX Nasdaq
- DYN Nasdaq
- Market Cap
- VTMX 2.2B
- DYN 2.6B
- IPO Year
- VTMX 2023
- DYN 2020
- Fundamental
- Price
- VTMX $26.15
- DYN $23.97
- Analyst Decision
- VTMX Buy
- DYN Strong Buy
- Analyst Count
- VTMX 2
- DYN 11
- Target Price
- VTMX $33.50
- DYN $51.18
- AVG Volume (30 Days)
- VTMX 167.0K
- DYN 821.4K
- Earning Date
- VTMX 02-12-2025
- DYN 11-12-2024
- Dividend Yield
- VTMX 2.81%
- DYN N/A
- EPS Growth
- VTMX 2.33
- DYN N/A
- EPS
- VTMX 0.39
- DYN N/A
- Revenue
- VTMX $243,239,612.00
- DYN N/A
- Revenue This Year
- VTMX N/A
- DYN N/A
- Revenue Next Year
- VTMX $21.87
- DYN N/A
- P/E Ratio
- VTMX $6.36
- DYN N/A
- Revenue Growth
- VTMX 18.11
- DYN N/A
- 52 Week Low
- VTMX $23.32
- DYN $12.06
- 52 Week High
- VTMX $41.44
- DYN $47.45
- Technical
- Relative Strength Index (RSI)
- VTMX 58.60
- DYN 33.01
- Support Level
- VTMX $25.13
- DYN $23.31
- Resistance Level
- VTMX $26.23
- DYN $24.90
- Average True Range (ATR)
- VTMX 0.74
- DYN 1.38
- MACD
- VTMX 0.16
- DYN -0.30
- Stochastic Oscillator
- VTMX 95.40
- DYN 10.30
About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)
Corporacion Inmobiliaria Vesta SAB de CV is a real estate company dedicated to the development and leasing of industrial buildings and distribution centers in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenues is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.